多中心分析:服用GLP-1 RAs患者Roux-en-Y胃旁路术后酒精使用障碍的结局

IF 4.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Obesity Pub Date : 2025-08-26 DOI:10.1002/oby.70001
Olanrewaju Adeniran, Luis M. Nieto, Chima Amadi, Katherine Shepherd, Joshua Kirkpatrick, Kanith Farah, Farirai Marwizi, Budoor Alqinai, Sharon I. Narvaez, Samuel Mensah, Ayowumi Adekolu, Ethan M. Cohen, Raja S. Khan, Swapna Gayam, Lawrence E. Tabone, Laura Davisson
{"title":"多中心分析:服用GLP-1 RAs患者Roux-en-Y胃旁路术后酒精使用障碍的结局","authors":"Olanrewaju Adeniran,&nbsp;Luis M. Nieto,&nbsp;Chima Amadi,&nbsp;Katherine Shepherd,&nbsp;Joshua Kirkpatrick,&nbsp;Kanith Farah,&nbsp;Farirai Marwizi,&nbsp;Budoor Alqinai,&nbsp;Sharon I. Narvaez,&nbsp;Samuel Mensah,&nbsp;Ayowumi Adekolu,&nbsp;Ethan M. Cohen,&nbsp;Raja S. Khan,&nbsp;Swapna Gayam,&nbsp;Lawrence E. Tabone,&nbsp;Laura Davisson","doi":"10.1002/oby.70001","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Roux-en-Y gastric bypass (RYGB) has been linked with increased alcohol-related outcomes, whereas glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with reduced risks. We performed the first multicenter retrospective cohort study to identify alcohol use outcomes of GLP-1 RAs post RYGB.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using TriNetX, adults (≥ 18 years old) with obesity (BMI ≥ 30 kg/m<sup>2</sup>) who underwent RYGB between January 1, 2019, and May 31, 2023, were identified. Two cohorts were analyzed: patients initiated on GLP-1 RA versus non-GLP-1 RA users. Patients with other liver diseases and other bariatric surgeries were excluded. Covariates were balanced via propensity score matching (PSM). Participants were followed for at least 1 year post RYGB and GLP-1 RA initiation. Outcomes include the risk of alcohol use disorders (AUD), alcohol liver diseases (ALD), and all-cause mortality. Hazard ratio (HR) was calculated through Cox regression analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>After PSM, 3438 were matched in each cohort. GLP-1 RA initiation was associated with a reduced incidence rate of AUD versus control (1.1% vs. 1.8%) (HR 0.77, [95% CI: 0.549–0.840, <i>p</i> = 0.041]) and all-cause mortality (1.2% versus 3.9%) (HR 0.497, [95% CI: 0.346–0.715, <i>p</i> = 0.039]).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Post RYGB, GLP-1 RAs provide the potential to reduce AUD and all-cause mortality.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 10","pages":"1886-1894"},"PeriodicalIF":4.7000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis\",\"authors\":\"Olanrewaju Adeniran,&nbsp;Luis M. Nieto,&nbsp;Chima Amadi,&nbsp;Katherine Shepherd,&nbsp;Joshua Kirkpatrick,&nbsp;Kanith Farah,&nbsp;Farirai Marwizi,&nbsp;Budoor Alqinai,&nbsp;Sharon I. Narvaez,&nbsp;Samuel Mensah,&nbsp;Ayowumi Adekolu,&nbsp;Ethan M. Cohen,&nbsp;Raja S. Khan,&nbsp;Swapna Gayam,&nbsp;Lawrence E. Tabone,&nbsp;Laura Davisson\",\"doi\":\"10.1002/oby.70001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Roux-en-Y gastric bypass (RYGB) has been linked with increased alcohol-related outcomes, whereas glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with reduced risks. We performed the first multicenter retrospective cohort study to identify alcohol use outcomes of GLP-1 RAs post RYGB.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Using TriNetX, adults (≥ 18 years old) with obesity (BMI ≥ 30 kg/m<sup>2</sup>) who underwent RYGB between January 1, 2019, and May 31, 2023, were identified. Two cohorts were analyzed: patients initiated on GLP-1 RA versus non-GLP-1 RA users. Patients with other liver diseases and other bariatric surgeries were excluded. Covariates were balanced via propensity score matching (PSM). Participants were followed for at least 1 year post RYGB and GLP-1 RA initiation. Outcomes include the risk of alcohol use disorders (AUD), alcohol liver diseases (ALD), and all-cause mortality. Hazard ratio (HR) was calculated through Cox regression analysis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>After PSM, 3438 were matched in each cohort. GLP-1 RA initiation was associated with a reduced incidence rate of AUD versus control (1.1% vs. 1.8%) (HR 0.77, [95% CI: 0.549–0.840, <i>p</i> = 0.041]) and all-cause mortality (1.2% versus 3.9%) (HR 0.497, [95% CI: 0.346–0.715, <i>p</i> = 0.039]).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Post RYGB, GLP-1 RAs provide the potential to reduce AUD and all-cause mortality.</p>\\n </section>\\n </div>\",\"PeriodicalId\":215,\"journal\":{\"name\":\"Obesity\",\"volume\":\"33 10\",\"pages\":\"1886-1894\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/oby.70001\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.70001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:Roux-en-Y胃旁路术(RYGB)与酒精相关的预后增加有关,而胰高血糖素样肽-1受体激动剂(GLP-1 RAs)与风险降低有关。我们进行了首个多中心回顾性队列研究,以确定RYGB后GLP-1 RAs的酒精使用结果。方法:使用TriNetX对2019年1月1日至2023年5月31日期间接受RYGB治疗的肥胖成人(≥18岁)(BMI≥30 kg/m2)进行识别。分析了两个队列:开始使用GLP-1 RA的患者与非GLP-1 RA使用者。其他肝脏疾病和其他减肥手术的患者被排除在外。通过倾向得分匹配(PSM)平衡协变量。参与者在RYGB和GLP-1 RA开始后随访至少1年。结果包括酒精使用障碍(AUD)、酒精性肝病(ALD)和全因死亡率的风险。通过Cox回归分析计算风险比(HR)。结果:PSM后,每个队列匹配3438例。与对照组相比,GLP-1 RA起始与AUD发生率降低(1.1%对1.8%)(HR 0.77, [95% CI: 0.549-0.840, p = 0.041])和全因死亡率(1.2%对3.9%)(HR 0.497, [95% CI: 0.346-0.715, p = 0.039])相关。结论:RYGB后,GLP-1 RAs具有降低AUD和全因死亡率的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis

Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis

Objective

Roux-en-Y gastric bypass (RYGB) has been linked with increased alcohol-related outcomes, whereas glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with reduced risks. We performed the first multicenter retrospective cohort study to identify alcohol use outcomes of GLP-1 RAs post RYGB.

Methods

Using TriNetX, adults (≥ 18 years old) with obesity (BMI ≥ 30 kg/m2) who underwent RYGB between January 1, 2019, and May 31, 2023, were identified. Two cohorts were analyzed: patients initiated on GLP-1 RA versus non-GLP-1 RA users. Patients with other liver diseases and other bariatric surgeries were excluded. Covariates were balanced via propensity score matching (PSM). Participants were followed for at least 1 year post RYGB and GLP-1 RA initiation. Outcomes include the risk of alcohol use disorders (AUD), alcohol liver diseases (ALD), and all-cause mortality. Hazard ratio (HR) was calculated through Cox regression analysis.

Results

After PSM, 3438 were matched in each cohort. GLP-1 RA initiation was associated with a reduced incidence rate of AUD versus control (1.1% vs. 1.8%) (HR 0.77, [95% CI: 0.549–0.840, p = 0.041]) and all-cause mortality (1.2% versus 3.9%) (HR 0.497, [95% CI: 0.346–0.715, p = 0.039]).

Conclusions

Post RYGB, GLP-1 RAs provide the potential to reduce AUD and all-cause mortality.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Obesity
Obesity 医学-内分泌学与代谢
CiteScore
11.70
自引率
1.40%
发文量
261
审稿时长
2-4 weeks
期刊介绍: Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信